JP2016529312A5 - - Google Patents

Download PDF

Info

Publication number: JP2016529312A5
Authority: JP; Japan
Prior art keywords: alkyl; carbocyclyl; heterocyclyl; alkynyl; alkenyl
Prior art date: 2014-09-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2016540387A

Other languages

English (en)

Japanese (ja)

Other versions

JP6336598B2 (ja

JP2016529312A (ja

Filing date

2014-09-04

Publication date

2017-09-07

2014-09-04 Application filed filed Critical

2014-09-04 Priority claimed from PCT/US2014/054114 external-priority patent/WO2015035062A1/en

2016-09-23 Publication of JP2016529312A publication Critical patent/JP2016529312A/ja

2017-09-07 Publication of JP2016529312A5 publication Critical patent/JP2016529312A5/ja

2018-06-06 Application granted granted Critical

2018-06-06 Publication of JP6336598B2 publication Critical patent/JP6336598B2/ja

Status Expired - Fee Related legal-status Critical Current

2034-09-04 Anticipated expiration legal-status Critical

Links

0 CCC(*(C)C)=C*=C(*)[*@]1*=CC(C(C=**2C(C(CC)=C3C)=O)=C2*3=C)=C1 Chemical compound CCC(*(C)C)=C*=C(*)[*@]1*=CC(C(C=**2C(C(CC)=C3C)=O)=C2*3=C)=C1 0.000 description 4
CSLJXILIWIMLTL-UHFFFAOYSA-N CC(C)c1c[n](-c(nc2)ncc2N(C)C)nc1 Chemical compound CC(C)c1c[n](-c(nc2)ncc2N(C)C)nc1 CSLJXILIWIMLTL-UHFFFAOYSA-N 0.000 description 1
ZAZCIHKBUVQXKV-UHFFFAOYSA-N CC(Nc([n](C1=O)nc2)c2-c2c[n](-c3ccccn3)nc2)=C1Cl Chemical compound CC(Nc([n](C1=O)nc2)c2-c2c[n](-c3ccccn3)nc2)=C1Cl ZAZCIHKBUVQXKV-UHFFFAOYSA-N 0.000 description 1
XCJHHYWFOXAYBC-UHFFFAOYSA-N CC(c1c[n](-c2ccncn2)nc1)=C Chemical compound CC(c1c[n](-c2ccncn2)nc1)=C XCJHHYWFOXAYBC-UHFFFAOYSA-N 0.000 description 1
VVAMRKQTTRRZBC-LSDHQDQOSA-N CC/C(/[n]1cnc(-c2ccccn2)c1)=C(/NC(c1ccccc1)=C(CC)C1=O)\N1N Chemical compound CC/C(/[n]1cnc(-c2ccccn2)c1)=C(/NC(c1ccccc1)=C(CC)C1=O)\N1N VVAMRKQTTRRZBC-LSDHQDQOSA-N 0.000 description 1
LPLZTGZNKNRTLL-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2ccccn2)c1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2ccccn2)c1 LPLZTGZNKNRTLL-UHFFFAOYSA-N 0.000 description 1
UTTNHAMRKOCBMO-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2cccnc2)c1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-[n]1cnc(-c2cccnc2)c1 UTTNHAMRKOCBMO-UHFFFAOYSA-N 0.000 description 1
WWYNJDQPWNRJLC-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2cc(N(C)C)ccn2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2cc(N(C)C)ccn2)nc1 WWYNJDQPWNRJLC-UHFFFAOYSA-N 0.000 description 1
PQCIOURXCUVAEZ-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(Cl)c2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(Cl)c2)nc1 PQCIOURXCUVAEZ-UHFFFAOYSA-N 0.000 description 1
RTWAURZQZXFUNZ-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(OC)c2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2nccc(OC)c2)nc1 RTWAURZQZXFUNZ-UHFFFAOYSA-N 0.000 description 1
RMLRQNYPXZAZLZ-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2ncccn2)nc1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1c[n](-c2ncccn2)nc1 RMLRQNYPXZAZLZ-UHFFFAOYSA-N 0.000 description 1
ANRQHYNHPUYMMB-UHFFFAOYSA-N CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1cnc(-c2ccccn2)[nH]1 Chemical compound CCC(C([n]1nc2)=O)=C(C)Nc1c2-c1cnc(-c2ccccn2)[nH]1 ANRQHYNHPUYMMB-UHFFFAOYSA-N 0.000 description 1
JPEUQZVNSKXPHA-UHFFFAOYSA-N CNc1c[n](-c2nc(N(C)C)ccn2)nc1 Chemical compound CNc1c[n](-c2nc(N(C)C)ccn2)nc1 JPEUQZVNSKXPHA-UHFFFAOYSA-N 0.000 description 1
ZTDDWLMWLULANI-UHFFFAOYSA-N Cc1ccnc(-[n]2ncc(N)c2)n1 Chemical compound Cc1ccnc(-[n]2ncc(N)c2)n1 ZTDDWLMWLULANI-UHFFFAOYSA-N 0.000 description 1
XHRMXJNKNQKYRQ-UHFFFAOYSA-N O=C1[n]2ncc(-c3c[n](-c4ccccn4)nc3)c2NC2=C1CCC2 Chemical compound O=C1[n]2ncc(-c3c[n](-c4ccccn4)nc3)c2NC2=C1CCC2 XHRMXJNKNQKYRQ-UHFFFAOYSA-N 0.000 description 1

JP2016540387A 2013-09-05 2014-09-04 抗増殖性化合物 Expired - Fee Related JP6336598B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361874310P	2013-09-05	2013-09-05
US61/874,310		2013-09-05
PCT/US2014/054114 WO2015035062A1 (en)	2013-09-05	2014-09-04	Antiproliferative compounds

Publications (3)

Publication Number	Publication Date
JP2016529312A JP2016529312A (ja)	2016-09-23
JP2016529312A5 true JP2016529312A5 (2)	2017-09-07
JP6336598B2 JP6336598B2 (ja)	2018-06-06

Family

ID=51541384

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016540387A Expired - Fee Related JP6336598B2 (ja)	2013-09-05	2014-09-04	抗増殖性化合物

Country Status (9)

Country	Link
US (1)	US9505767B2 (2)
EP (1)	EP3041474B1 (2)
JP (1)	JP6336598B2 (2)
KR (1)	KR20160049003A (2)
CN (1)	CN105611933B (2)
CA (1)	CA2922925A1 (2)
MX (1)	MX2016002794A (2)
RU (1)	RU2016112568A (2)
WO (1)	WO2015035062A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS55764B1 (sr)	2012-10-02	2017-07-31	Gilead Sciences	Inhibitori histonskih demetilaza
CA2901022C (en)	2013-02-27	2021-05-04	Epitherapeutics Aps	Substituted pyridine compounds as inhibitors of histone demethylases
WO2014139326A1 (en)	2013-03-13	2014-09-18	Genentech, Inc.	Pyrazolo compounds and uses thereof
SG11201701182VA (en)	2014-08-27	2017-03-30	Gilead Sciences Inc	Compounds and methods for inhibiting histone demethylases
NZ730475A (en)	2014-10-29	2018-09-28	Dong A St Co Ltd	Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
EP3294313A4 (en) *	2015-05-15	2019-04-17	The General Hospital Corporation	METHODS RELATING TO THE PREVENTION AND TREATMENT OF DRUG RESISTANCE
CR20190157A (es)	2016-08-31	2019-08-13	Agios Pharmaceuticals Inc	Inhibidores de procesos metabólicos celulares
US10975084B2 (en)	2016-10-12	2021-04-13	Merck Sharp & Dohme Corp.	KDM5 inhibitors
US20200048259A1 (en) *	2016-10-12	2020-02-13	Merck Sharp & Dohme Corp.	Kdm5 inhibitors
WO2018160356A1 (en)	2017-02-28	2018-09-07	University Of Massachusetts	Genetic and pharmacological transcriptional upregulation of the repressed fxn gene as a therapeutic strategy for friedreich ataxia
CN108947985A (zh) *	2017-05-22	2018-12-07	苏州偶领生物医药有限公司	用作自噬调节剂的化合物及其制备方法和用途
JP2020531519A (ja)	2017-08-21	2020-11-05	ナビゲン，インコーポレーテッド	Ａｒｆ６阻害剤及び関連する方法
MX2020002869A (es) *	2017-09-15	2020-07-24	Aduro Biotech Inc	Compuestos de pirazolopirimidinona y usos de los mismos.
EP3990460A4 (en) *	2019-06-24	2023-04-12	Dana-Farber Cancer Institute, Inc.	E3 LIGASE BINDERS AND THEIR USES
JP2022541954A (ja) *	2019-07-17	2022-09-28	小野薬品工業株式会社	Ｋｄｍ５阻害活性を有する化合物およびその医薬用途
KR102598203B1 (ko)	2019-11-25	2023-11-03	암젠 인크	델타-5 불포화효소 억제제로서의 헤테로시클릭 화합물 및 사용 방법
WO2023134692A1 (zh) *	2022-01-13	2023-07-20	浙江同源康医药股份有限公司	多环类化合物及其用途
UY40234A (es)	2022-04-22	2023-11-15	Vertex Pharma	Compuestos heteroarilo para el tratamiento del dolor
EP4615431A1 (en)	2022-11-11	2025-09-17	Astrazeneca AB	Combination therapies for the treatment of cancer
WO2025194015A1 (en) *	2024-03-15	2025-09-18	Dem Biopharma, Inc.	Heteroaryl modulators of gpr84 and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU22545A1 (es)	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en)	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
EP0491007B1 (en)	1989-09-08	1996-03-13	The Johns Hopkins University	Structural alterations of the egf receptor gene in human gliomas
US5356897A (en) *	1991-09-09	1994-10-18	Fujisawa Pharmaceutical Co., Ltd.	3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
AU661533B2 (en)	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
GB9314893D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
EP0659439B1 (en)	1993-12-24	2001-10-24	MERCK PATENT GmbH	Immunoconjugates
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en)	1994-01-25	1997-10-21	Warner-Lambert Company	Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
PL179659B1 (pl)	1994-07-21	2000-10-31	Akzo Nobel Nv	Kompozycja cyklicznych nadtlenków ketonów sluzaca do modyfikowania (ko)polimerów zwlaszcza do degradacji polipropylenu PL PL PL PL PL PL PL
US5804396A (en)	1994-10-12	1998-09-08	Sugen, Inc.	Assay for agents active in proliferative disorders
MX9707453A (es)	1995-03-30	1997-12-31	Pfizer	Derivados de quinazolina.
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508565D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en)	1995-06-07	1996-12-30	Imclone Systems Incorporated	Antibody and antibody fragments for inhibiting the growth oftumors
MX9800215A (es)	1995-07-06	1998-03-31	Novartis Ag	Pirrolopirimidas y procesos para su preparacion.
US5760041A (en)	1996-02-05	1998-06-02	American Cyanamid Company	4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
HU228446B1 (en)	1996-04-12	2013-03-28	Warner Lambert Co	Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
ID19609A (id)	1996-07-13	1998-07-23	Glaxo Group Ltd	Senyawa-senyawa heterosiklik
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
ATE241986T1 (de)	1997-05-06	2003-06-15	Wyeth Corp	Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit
ZA986729B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
CN1278176A (zh)	1997-11-06	2000-12-27	美国氰胺公司	喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用
WO2000031048A1 (en)	1998-11-19	2000-06-02	Warner-Lambert Company	N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
JP4100865B2 (ja) *	1999-12-13	2008-06-11	エーザイ・アール・アンド・ディー・マネジメント株式会社	三環式縮合異項環化合物、その製造法およびその医薬
TWI271406B (en) *	1999-12-13	2007-01-21	Eisai Co Ltd	Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
US7196111B2 (en)	2002-06-04	2007-03-27	Schering Corporation	Pyrazolo[1,5a]pyrimidine compounds as antiviral agents
US7605155B2 (en) *	2002-09-04	2009-10-20	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
ES2559679T3 (es) *	2006-06-20	2016-02-15	Abbvie Inc.	Pirazoloquinazolinonas como inhibidores de PARP
WO2010086040A1 (en)	2009-01-29	2010-08-05	Biomarin Iga, Ltd.	Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
CN101906105B (zh) *	2009-06-08	2013-01-16	河北医科大学	吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途
WO2012149157A2 (en) *	2011-04-26	2012-11-01	Bioenergenix	Heterocyclic compounds for the inhibition of pask
WO2014066795A1 (en)	2012-10-25	2014-05-01	Bioenergenix	Heterocyclic compounds for the inhibition of pask
JP6338601B2 (ja) *	2013-03-01	2018-06-06	フンダシオンパララインベスティガシオンメディカアプリカダ	ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物
WO2014139326A1 (en)	2013-03-13	2014-09-18	Genentech, Inc.	Pyrazolo compounds and uses thereof

2014
- 2014-09-04 MX MX2016002794A patent/MX2016002794A/es unknown
- 2014-09-04 WO PCT/US2014/054114 patent/WO2015035062A1/en not_active Ceased
- 2014-09-04 CN CN201480055129.0A patent/CN105611933B/zh active Active
- 2014-09-04 EP EP14766355.3A patent/EP3041474B1/en active Active
- 2014-09-04 US US14/477,566 patent/US9505767B2/en active Active
- 2014-09-04 RU RU2016112568A patent/RU2016112568A/ru not_active Application Discontinuation
- 2014-09-04 KR KR1020167008823A patent/KR20160049003A/ko not_active Withdrawn
- 2014-09-04 CA CA2922925A patent/CA2922925A1/en not_active Abandoned
- 2014-09-04 JP JP2016540387A patent/JP6336598B2/ja not_active Expired - Fee Related

Publication	Publication Date	Title
JP2016529312A5 (2)	2017-09-07
RU2016112568A (ru)	2017-10-06	Антипролиферативные соединения
JP2017530984A5 (2)	2018-11-22
JP2018505169A5 (2)	2019-03-07
ES2694513T3 (es)	2018-12-21	Derivado de quinolina
IL275333B2 (en)	2023-09-01	Inhibitors of fibroblast activation protein
JP2018510851A5 (2)	2019-03-07
JP2017528475A5 (2)	2018-10-18
JP2016525075A5 (2)	2017-07-20
RU2018103944A (ru)	2019-08-16	Производные этинила как модуляторы метаботропного рецептора глутамата
JP2018520195A5 (2)	2019-08-15
JP2010522194A5 (2)	2012-05-10
EA201690531A1 (ru)	2016-08-31	ПРОИЗВОДНЫЕ 1-(5-ТРЕТ-БУТИЛ-2-АРИЛПИРАЗОЛ-3-ИЛ)-3-[2-ФТОР-4-[(3-ОКСО-4H-ПИРИДО[2,3-b]ПИРАЗИН-8-ИЛ)ОКСИ]ФЕНИЛ]МОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ RAF ДЛЯ ЛЕЧЕНИЯ РАКА
RU2014152790A (ru)	2016-08-10	Пирролопиразоновые ингибиторы танкиразы
JP2016504365A5 (2)	2016-11-24
RU2008136188A (ru)	2010-03-20	Противораковая фармацевтическая композиция
CN107548391A (zh)	2018-01-05	嘧啶或吡啶类化合物、其制备方法和医药用途
RU2016130932A (ru)	2018-03-13	Производные хинолона как ингибиторы рецептора фактора роста фибробластов
RU2015116749A (ru)	2016-12-20	Антагонисты mglu2/3 для лечения аутических расстройств
RU2016118753A (ru)	2017-11-29	Производные пиридилкетона, способ их получения и их фармацевтическое применение
RU2013147823A (ru)	2015-05-10	(альфа-замещенные аралкиламино-и гетероарилалкиламино)пиримидинил-и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний
KR20150081344A (ko)	2015-07-13	조합 요법
EP3053578B1 (en)	2020-12-23	Combination cancer therapy using azabicyclo compound
RU2016138676A (ru)	2018-04-13	Ингибиторы усилителя zeste гомолога 2
JP2018507191A5 (2)	2019-03-07